IBDEI0M1 ; ; 12-MAY-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 12, 2016
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,22220,1,4,0)
 ;;=4^C82.30
 ;;^UTILITY(U,$J,358.3,22220,2)
 ;;=^5001491
 ;;^UTILITY(U,$J,358.3,22221,0)
 ;;=C82.49^^89^1046^72
 ;;^UTILITY(U,$J,358.3,22221,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22221,1,3,0)
 ;;=3^Follicular Lymphoma Grade IIIb,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,22221,1,4,0)
 ;;=4^C82.49
 ;;^UTILITY(U,$J,358.3,22221,2)
 ;;=^5001510
 ;;^UTILITY(U,$J,358.3,22222,0)
 ;;=C82.40^^89^1046^73
 ;;^UTILITY(U,$J,358.3,22222,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22222,1,3,0)
 ;;=3^Follicular Lymphoma Grade IIIb,Unspec Site
 ;;^UTILITY(U,$J,358.3,22222,1,4,0)
 ;;=4^C82.40
 ;;^UTILITY(U,$J,358.3,22222,2)
 ;;=^5001501
 ;;^UTILITY(U,$J,358.3,22223,0)
 ;;=C82.99^^89^1046^74
 ;;^UTILITY(U,$J,358.3,22223,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22223,1,3,0)
 ;;=3^Follicular Lymphoma Unspec,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,22223,1,4,0)
 ;;=4^C82.99
 ;;^UTILITY(U,$J,358.3,22223,2)
 ;;=^5001550
 ;;^UTILITY(U,$J,358.3,22224,0)
 ;;=C82.90^^89^1046^75
 ;;^UTILITY(U,$J,358.3,22224,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22224,1,3,0)
 ;;=3^Follicular Lymphoma Unspec,Unspec Site
 ;;^UTILITY(U,$J,358.3,22224,1,4,0)
 ;;=4^C82.90
 ;;^UTILITY(U,$J,358.3,22224,2)
 ;;=^5001541
 ;;^UTILITY(U,$J,358.3,22225,0)
 ;;=R59.1^^89^1046^60
 ;;^UTILITY(U,$J,358.3,22225,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22225,1,3,0)
 ;;=3^Enlarged Lymph Nodes,Generalized
 ;;^UTILITY(U,$J,358.3,22225,1,4,0)
 ;;=4^R59.1
 ;;^UTILITY(U,$J,358.3,22225,2)
 ;;=^5019530
 ;;^UTILITY(U,$J,358.3,22226,0)
 ;;=C91.40^^89^1046^79
 ;;^UTILITY(U,$J,358.3,22226,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22226,1,3,0)
 ;;=3^Hairy Cell Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,22226,1,4,0)
 ;;=4^C91.40
 ;;^UTILITY(U,$J,358.3,22226,2)
 ;;=^5001771
 ;;^UTILITY(U,$J,358.3,22227,0)
 ;;=C91.42^^89^1046^77
 ;;^UTILITY(U,$J,358.3,22227,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22227,1,3,0)
 ;;=3^Hairy Cell Leukemia,In Relapse
 ;;^UTILITY(U,$J,358.3,22227,1,4,0)
 ;;=4^C91.42
 ;;^UTILITY(U,$J,358.3,22227,2)
 ;;=^5001773
 ;;^UTILITY(U,$J,358.3,22228,0)
 ;;=C91.41^^89^1046^78
 ;;^UTILITY(U,$J,358.3,22228,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22228,1,3,0)
 ;;=3^Hairy Cell Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,22228,1,4,0)
 ;;=4^C91.41
 ;;^UTILITY(U,$J,358.3,22228,2)
 ;;=^5001772
 ;;^UTILITY(U,$J,358.3,22229,0)
 ;;=D57.01^^89^1046^80
 ;;^UTILITY(U,$J,358.3,22229,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22229,1,3,0)
 ;;=3^Hb-SS Disease w/ Acute Chest Syndrome
 ;;^UTILITY(U,$J,358.3,22229,1,4,0)
 ;;=4^D57.01
 ;;^UTILITY(U,$J,358.3,22229,2)
 ;;=^5002307
 ;;^UTILITY(U,$J,358.3,22230,0)
 ;;=D57.00^^89^1046^81
 ;;^UTILITY(U,$J,358.3,22230,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22230,1,3,0)
 ;;=3^Hb-SS Disease w/ Crisis,Unspec
 ;;^UTILITY(U,$J,358.3,22230,1,4,0)
 ;;=4^D57.00
 ;;^UTILITY(U,$J,358.3,22230,2)
 ;;=^5002306
 ;;^UTILITY(U,$J,358.3,22231,0)
 ;;=D57.02^^89^1046^82
 ;;^UTILITY(U,$J,358.3,22231,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22231,1,3,0)
 ;;=3^Hb-SS Disease w/ Splenic Sequestration
 ;;^UTILITY(U,$J,358.3,22231,1,4,0)
 ;;=4^D57.02
 ;;^UTILITY(U,$J,358.3,22231,2)
 ;;=^5002308
 ;;^UTILITY(U,$J,358.3,22232,0)
 ;;=D68.32^^89^1046^84
 ;;^UTILITY(U,$J,358.3,22232,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22232,1,3,0)
 ;;=3^Hemorrhagic Disorder d/t Extrinsic Circulating Anticoagulants
 ;;^UTILITY(U,$J,358.3,22232,1,4,0)
 ;;=4^D68.32
 ;;^UTILITY(U,$J,358.3,22232,2)
 ;;=^5002357
 ;;^UTILITY(U,$J,358.3,22233,0)
 ;;=C22.2^^89^1046^85
 ;;^UTILITY(U,$J,358.3,22233,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22233,1,3,0)
 ;;=3^Hepatoblastoma
 ;;^UTILITY(U,$J,358.3,22233,1,4,0)
 ;;=4^C22.2
 ;;^UTILITY(U,$J,358.3,22233,2)
 ;;=^5000935
 ;;^UTILITY(U,$J,358.3,22234,0)
 ;;=D58.9^^89^1046^87
 ;;^UTILITY(U,$J,358.3,22234,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22234,1,3,0)
 ;;=3^Hereditary Hemolytic Anemia,Unspec
 ;;^UTILITY(U,$J,358.3,22234,1,4,0)
 ;;=4^D58.9
 ;;^UTILITY(U,$J,358.3,22234,2)
 ;;=^5002322
 ;;^UTILITY(U,$J,358.3,22235,0)
 ;;=C81.99^^89^1046^88
 ;;^UTILITY(U,$J,358.3,22235,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22235,1,3,0)
 ;;=3^Hodgkin Lymphoma,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,22235,1,4,0)
 ;;=4^C81.99
 ;;^UTILITY(U,$J,358.3,22235,2)
 ;;=^5001460
 ;;^UTILITY(U,$J,358.3,22236,0)
 ;;=C81.90^^89^1046^89
 ;;^UTILITY(U,$J,358.3,22236,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22236,1,3,0)
 ;;=3^Hodgkin Lymphoma,Unspec Site
 ;;^UTILITY(U,$J,358.3,22236,1,4,0)
 ;;=4^C81.90
 ;;^UTILITY(U,$J,358.3,22236,2)
 ;;=^5001451
 ;;^UTILITY(U,$J,358.3,22237,0)
 ;;=D89.2^^89^1046^90
 ;;^UTILITY(U,$J,358.3,22237,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22237,1,3,0)
 ;;=3^Hypergammaglobulenemia,Unspec
 ;;^UTILITY(U,$J,358.3,22237,1,4,0)
 ;;=4^D89.2
 ;;^UTILITY(U,$J,358.3,22237,2)
 ;;=^5002455
 ;;^UTILITY(U,$J,358.3,22238,0)
 ;;=D05.12^^89^1046^91
 ;;^UTILITY(U,$J,358.3,22238,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22238,1,3,0)
 ;;=3^Intraductal Carcinoma in Situ,Left Breast
 ;;^UTILITY(U,$J,358.3,22238,1,4,0)
 ;;=4^D05.12
 ;;^UTILITY(U,$J,358.3,22238,2)
 ;;=^5001931
 ;;^UTILITY(U,$J,358.3,22239,0)
 ;;=D05.11^^89^1046^92
 ;;^UTILITY(U,$J,358.3,22239,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22239,1,3,0)
 ;;=3^Intraductal Carcinoma in Situ,Right Breast
 ;;^UTILITY(U,$J,358.3,22239,1,4,0)
 ;;=4^D05.11
 ;;^UTILITY(U,$J,358.3,22239,2)
 ;;=^5001930
 ;;^UTILITY(U,$J,358.3,22240,0)
 ;;=D05.10^^89^1046^93
 ;;^UTILITY(U,$J,358.3,22240,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22240,1,3,0)
 ;;=3^Intraductal Carcinoma in Situ,Unspec Breast
 ;;^UTILITY(U,$J,358.3,22240,1,4,0)
 ;;=4^D05.10
 ;;^UTILITY(U,$J,358.3,22240,2)
 ;;=^5001929
 ;;^UTILITY(U,$J,358.3,22241,0)
 ;;=D50.0^^89^1046^94
 ;;^UTILITY(U,$J,358.3,22241,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22241,1,3,0)
 ;;=3^Iron Deficiency Anemia Secondary to Blood Loss
 ;;^UTILITY(U,$J,358.3,22241,1,4,0)
 ;;=4^D50.0
 ;;^UTILITY(U,$J,358.3,22241,2)
 ;;=^267971
 ;;^UTILITY(U,$J,358.3,22242,0)
 ;;=D50.9^^89^1046^95
 ;;^UTILITY(U,$J,358.3,22242,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22242,1,3,0)
 ;;=3^Iron Deficiency Anemia,Unspec
 ;;^UTILITY(U,$J,358.3,22242,1,4,0)
 ;;=4^D50.9
 ;;^UTILITY(U,$J,358.3,22242,2)
 ;;=^5002283
 ;;^UTILITY(U,$J,358.3,22243,0)
 ;;=C46.9^^89^1046^96
 ;;^UTILITY(U,$J,358.3,22243,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22243,1,3,0)
 ;;=3^Kaposi's Sarcoma,Unspec
 ;;^UTILITY(U,$J,358.3,22243,1,4,0)
 ;;=4^C46.9
 ;;^UTILITY(U,$J,358.3,22243,2)
 ;;=^5001108
 ;;^UTILITY(U,$J,358.3,22244,0)
 ;;=C22.0^^89^1046^97
 ;;^UTILITY(U,$J,358.3,22244,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22244,1,3,0)
 ;;=3^Liver Cell Carcinoma
 ;;^UTILITY(U,$J,358.3,22244,1,4,0)
 ;;=4^C22.0
 ;;^UTILITY(U,$J,358.3,22244,2)
 ;;=^5000933
 ;;^UTILITY(U,$J,358.3,22245,0)
 ;;=D05.02^^89^1046^98
 ;;^UTILITY(U,$J,358.3,22245,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22245,1,3,0)
 ;;=3^Lobular Carcinoma in Situ,Left Breast
 ;;^UTILITY(U,$J,358.3,22245,1,4,0)
 ;;=4^D05.02
 ;;^UTILITY(U,$J,358.3,22245,2)
 ;;=^5001928
 ;;^UTILITY(U,$J,358.3,22246,0)
 ;;=D05.01^^89^1046^99
 ;;^UTILITY(U,$J,358.3,22246,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22246,1,3,0)
 ;;=3^Lobular Carcinoma in Situ,Right Breast
 ;;^UTILITY(U,$J,358.3,22246,1,4,0)
 ;;=4^D05.01
 ;;^UTILITY(U,$J,358.3,22246,2)
 ;;=^5001927
 ;;^UTILITY(U,$J,358.3,22247,0)
 ;;=D05.00^^89^1046^100
 ;;^UTILITY(U,$J,358.3,22247,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22247,1,3,0)
 ;;=3^Lobular Carcinoma in Situ,Unspec Breast
 ;;^UTILITY(U,$J,358.3,22247,1,4,0)
 ;;=4^D05.00
 ;;^UTILITY(U,$J,358.3,22247,2)
 ;;=^5001926
 ;;^UTILITY(U,$J,358.3,22248,0)
 ;;=R59.0^^89^1046^61
